No spam - just the good stuff

Subscribe to our newsletter
Hidden
  • News
  • Investor Portal
  • Lifestyle
  • Videos

News

  • Home
  • Biotech
  • Investment
  • Diagnostics
  • Agetech
  • Supplements
  • Innovation
  • AI/Digital
  • Economy

InvestmentInvestor Portal

  • Investment portal
  • Investment portal login
  • Register as an investor
  • Raise finance

Lifestyle

  • Home
  • Supplements
  • Self-testing
  • Exercise
  • Nutrition
  • Tech
  • Mental wellness
  • Product reviews

More

  • Contact
  • Features

News

  • Home
  • Biotech
  • Investment
  • Diagnostics
  • Agetech
  • Supplements
  • Innovation
  • AI/Digital
  • Economy

Salvinija Roznyte

About

Staff Writer

Salvinija Roznyte is a writer and journalist based in London. She graduated in 2018 with a Bachelor's degree majoring in Writing and Journalism with a minor in Film Studies. She is interested in the way modern medical technology changes and shapes our world.

36 POSTS   |   0 COMMENTS
Articles

First Longevity AI Consortium launched at King’s

AI AI/Digital Investment Investment

UK doctors told to ignore consumer genetic tests

Investment Investment

New study shows rapamycin slows Alzheimer’s

Biotech Drugs Indication expansion

60 new Biotech and Agetech start-ups to join showcase

Agetech Biotech Cellular Investment Senescence

Human Longevity, Inc: $30m injection. Challenges?

Investment Investment

Ervaxx exits stealth mode with $17.5 million

Biotech Cellular Gene editing Investment

The Longevity biotech industry is hitting its stride

Economy Innovation Investment Investment Tissue/Organ

3D bioprinting breakthrough in vascular systems

3D Bio-printing Innovation Tissue/Organ

Insilico’s Dr Alex Zhavoronkov defines Longevity

AI AI/Digital Biotech Development Drugs
← Older posts

Find us here ...

Subscribe to our newsletter

Hidden

News

  • Home
  • Biotech
  • Investment
  • Diagnostics
  • Agetech
  • Supplements
  • Innovation
  • AI/Digital
  • Economy

Investment

  • Investment portal
  • Investment portal login
  • Register as an investor
  • Raise finance

Lifestyle

  • Home
  • Supplements
  • Self-testing
  • Exercise
  • Nutrition
  • Tech
  • Mental wellness
  • Product reviews

More

  • Contact
  • Features
  • Editorial Policy
  • Privacy Policy
  • Cookie Policy
  • Conditions of Business
  • Terms and Conditions
  • Copyright Policy
© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY
The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS
The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.